“Ideal” parathyroid hormone in erythropoietin‐stimulating agents‐resistant anemia

Erythropoietin‐stimulating agents (ESAs) have revolutionized anemia treatment in end‐stage renal disease (ESRD), but ESA resistance is increasingly identified. Secondary hyperparathyroidism (SHP) is one cause of ESA resistance. We describe a patient with ESA‐resistant, transfusion‐dependent anemia a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashraf, Bilal, Bat, Taha, Weinberg, Olga K., Moe, Orson W., Ibrahim, Ibrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176131/
https://www.ncbi.nlm.nih.gov/pubmed/35846199
http://dx.doi.org/10.1002/jha2.316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176131/
https://www.ncbi.nlm.nih.gov/pubmed/35846199
http://dx.doi.org/10.1002/jha2.316

Ejemplares similares